EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
ENSAYO CLÍNICO CON MEDICAMENTOS
Información del ensayo clínico
- Promotor: LILLY, S.A.
- Fase: III
- Comienzo de la ejecución: 08/12/2022
- Fin de la ejecución: 30/03/2025
- IP: ISABEL BLANCAS LOPEZ-BARAJAS
